不孕不育药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物类别(促性腺激素、芳香酶抑制剂、选择性雌激素受体调节剂 (SERM)、双胍类和其他药物类别)、最终用户(男性和女性)、分销渠道和地理位置进行细分

市场快照

infertility drugs market share
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.69 %
infertility drugs market key players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

研究的不孕症药物市场预计在预测期内的复合年增长率为 6.1%。促成市场增长的主要因素是生活方式的显着变化,这导致(PCOS)多囊卵巢综合征病例、泌尿癌和乳腺癌的数量增加。癌症患病率的上升导致辐射暴露增加,从而导致不孕。根据美国卫生与公众服务部 (HHS) 的报告,2019 年,PCOS 是一个主要的健康问题,影响全球十分之一的育龄妇女。因此,导致生育率下降的妇科疾病上升可能会推动全球不孕症药物市场。

报告范围

不孕症是指女性在一年(或更长时间)无保护性行为后无法怀孕。男性和女性的生育率随着年龄在 35 岁或以上而下降。报告中讨论了用于治疗不孕症的各种药物。

By Drug Class
Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End-user
Male
Female
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

女性不孕症药物板块有望占据不孕症药物市场的主要市场份额

女性不孕症药物部分预计将在预测期内主导该行业。该细分市场利润丰厚的增长可归因于不孕症和误解的更高发生率(因为女性与男性相比)。女性不孕不育的主要原因是甲状腺癌和乳腺癌的患病率增加,这需要更多的辐射暴露,导致生育率急剧下降。例如,根据美国国立卫生研究院公布的情况说明书,女性的生育率在 30 多岁时下降了一半。报告指出,女性受孕机会在 35.6 岁后显着下降,而男性生育能力逐渐下降,并且在患有任何类型癌症的女性中。吸烟和饮酒的增加以及各种疾病的发病率增加,如 PCOS 和子宫肌瘤,导致需求增加。预计这一因素将推动该部门的增长。

infertility drugs market trends

北美在市场上占主导地位,预计在预测期内也会如此。

预计北美将在预测期内主导全球不孕症药物市场。这种主导地位主要是由于更年期疾病、泌尿感染、甲状腺问题、子宫内膜异位症和其他由于忙碌的生活方式和女性压力增加而导致的发病率上升。根据 2019 年发布的疾病控制和预防中心 CDC 报告,PCOS 影响了大约 6% 到 12%,代表超过 500 万育龄妇女。此外,美国男性中少精子症、精索静脉曲张、糖尿病和其他疾病的急剧上升推动了该地区的收入份额。此外,更多生殖内分泌学家的存在以及先进的医疗保健基础设施推动了美国市场的增长。

infertility drugs market analysis

竞争格局

全球不孕不育药物市场竞争适度,由几个主要参与者组成。市场上的一些知名参与者正在实施各种策略,例如推出新产品和进行收购以巩固其在全球的市场地位。此外,用于开发这些药物的公共资金的急剧增加也有望推动市场发展。2019 年 12 月,艾尔建宣布其产品 PrFIBRISTAL 通过安大略省药物福利 (ODB) 处方集和非保险健康福利 (NIHB) 计划获得公共资助。PrFIBRISTAL 用于治疗导致不孕的子宫肌瘤的一流药物。子宫肌瘤是最常见的妇科肿瘤,影响几乎三分之一的加拿大育龄妇女。这种令人鼓舞的公共资金,治疗不孕症的创新方法可能会在预测期内对市场产生积极影响。目前主导市场的一些公司是 Ferring Pharmaceuticals Inc.、Merck KGaA、Bayer AG、Pfizer Inc. 和 Novartis AG

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of Stress and Life-style Disorders among Men and Women

      2. 4.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework that Delays the Approval of Products

      2. 4.3.2 Expensive Patented Products

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Gonadotrophins

      2. 5.1.2 Aromatase Inhibitors

      3. 5.1.3 Selective Estrogen Receptor Modulators (SERMs)

      4. 5.1.4 Biguanides

      5. 5.1.5 Other Drug Classes

    2. 5.2 By End-user

      1. 5.2.1 Male

      2. 5.2.2 Female

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Other Distribution Channels

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Takeda Pharmaceutical Company Limited

      3. 6.1.3 Ferring Pharmaceuticals Inc.

      4. 6.1.4 Merck KGaA.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Bayer AG

      8. 6.1.8 Theramex

      9. 6.1.9 Mankind Pharma

      10. 6.1.10 Teva Pharmaceticals Industries

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Infertility Drugs Market market is studied from 2018 - 2026.

The Infertility Drugs Market is growing at a CAGR of 4.69% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Ferring Pharmaceuticals Inc, Merck KGaA., Pfizer Inc., Novartis International AG, Bayer AG are the major companies operating in Infertility Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!